Natera, Inc. (NASDAQ:NTRA) Insider Sells $89,550.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 1,000 shares of the business’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $89.55, for a total transaction of $89,550.00. Following the sale, the insider now owns 69,082 shares in the company, valued at $6,186,293.10. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Jonathan Sheena also recently made the following trade(s):

• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The stock was sold at an average price of $92.47, for a total value of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The shares were sold at an average price of $90.22, for a total value of $40,328.34.
• On Tuesday, March 5th, Jonathan Sheena sold 1,028 shares of Natera stock. The stock was sold at an average price of $88.36, for a total value of $90,834.08.
• On Tuesday, February 6th, Jonathan Sheena sold 6,000 shares of Natera stock. The stock was sold at an average price of $70.00, for a total value of $420,000.00.

Natera Stock Up 0.4 %

NTRA traded up $0.38 on Friday, reaching $91.66. 568,943 shares of the company traded hands, compared to its average volume of 1,445,065. The stock’s 50 day moving average price is $87.72 and its 200-day moving average price is $67.16. Natera, Inc. has a 52-week low of $36.90 and a 52-week high of $98.82. The company has a market cap of $11.07 billion, a price-to-earnings ratio of -24.18 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96.

Natera (NASDAQ:NTRA) last announced its quarterly earnings data on Wednesday, February 28th. The medical research company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.73) by $0.09. Natera had a negative net margin of 40.16% and a negative return on equity of 62.19%. The firm had revenue of $311.11 million for the quarter, compared to the consensus estimate of $300.38 million. On average, sell-side analysts expect that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have recently weighed in on NTRA. Piper Sandler raised their price objective on shares of Natera from $70.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, March 6th. Craig Hallum began coverage on shares of Natera in a research note on Monday, April 8th. They issued a “buy” rating and a $117.00 price objective on the stock. Sanford C. Bernstein raised shares of Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price objective on the stock in a research note on Friday, April 5th. The Goldman Sachs Group lifted their price objective on shares of Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. Finally, Stephens reaffirmed an “overweight” rating and issued a $78.00 price objective on shares of Natera in a research note on Tuesday, January 30th. One investment analyst has rated the stock with a sell rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $86.40.

Institutional Trading of Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. RiverPark Advisors LLC acquired a new stake in Natera in the fourth quarter valued at approximately $27,000. Principal Securities Inc. acquired a new stake in Natera in the fourth quarter valued at approximately $32,000. YHB Investment Advisors Inc. acquired a new stake in Natera in the first quarter valued at approximately $36,000. Harvest Fund Management Co. Ltd acquired a new stake in Natera in the third quarter valued at approximately $44,000. Finally, Oliver Lagore Vanvalin Investment Group lifted its stake in Natera by 109.3% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock valued at $47,000 after acquiring an additional 389 shares during the last quarter. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.